Background In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial, apixaban (versus warfarin) significantly reduced stroke …

Background A previous FDA study reported a favorable benefit risk for apixaban compared
with warfarin for stroke prevention in older non-valvular atrial fibrillation (NVAF) patients (≥ …

Background and aim Atrial fibrillation (AF) is the most frequently observed cardiac
arrhythmia in clinical settings. Obesity can influence the efficacy of the treatment …

Objective: To investigate the risk of bleeding events and stroke/systemic embolism (SE)
among Japanese patients with nonvalvular atrial fibrillation (NVAF), focusing on the initial …

The prevalence of both atrial fibrillation (AF) and obesity has steadily increased. Nonvitamin
K antagonist oral anticoagulants (NOACs) have been shown to be more effective and safer …

Background: Atrial fibrillation (AF) increases the risk of stroke and direct oral anticoagulants
(DOACs) are first-line agents for prevention. Gaps in the literature cause reluctance in …

Aims: Observational studies of various dose levels of direct oral anticoagulants (DOACs) for
patients with atrial fibrillation (AF) found that a high proportion of patients received a dose …

This study aims to provide real-world data about starting-dose of NOACs and dose-
adjustment in patients with atrial fibrillation (AF). In fact, even if new oral anticoagulation …

Background: Atrial fibrillation (AF) and obesity are common conditions globally; yet, there
remains suboptimal pharmacological management contributing to high rates of …

Abstract Study Objective Observational studies assessing direct oral anticoagulant (DOACs)
dosage in atrial fibrillation (AF) reported that a lower proportion of patients received high …